| Record Information |
|---|
| Version | 2.0 |
|---|
| Created at | 2022-05-11 16:37:46 UTC |
|---|
| Updated at | 2022-05-11 16:37:46 UTC |
|---|
| NP-MRD ID | NP0087026 |
|---|
| Secondary Accession Numbers | None |
|---|
| Natural Product Identification |
|---|
| Common Name | Stanozolol |
|---|
| Description | Stanozolol, also known as winstrol or stromba, belongs to the class of organic compounds known as estrane steroids. These are steroids with a structure based on the estrane skeleton. Stanozolol is a moderately basic compound (based on its pKa). An organic heteropentacyclic compound resulting from the formal condensation of the 3-keto-aldehyde moiety of oxymetholone with hydrazine. It has also been widely abused by professional athletes. It has both anabolic and androgenic properties, and has been used to treat hereditary angioedema and various vascular disorders. Stanozolol was first documented in 1998 (PMID: 10435307). Like oxymetholone, it is a synthetic anabolic steroid (PMID: 15013688) (PMID: 10404632) (PMID: 11175645) (PMID: 11284331). |
|---|
| Structure | [H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=NNC=C3C[C@]12C InChI=1S/C21H32N2O/c1-19-11-13-12-22-23-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,24H,4-11H2,1-3H3,(H,22,23)/t14-,15+,16-,17-,19-,20-,21-/m0/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| Androstanazole | ChEBI | | Estanozolol | ChEBI | | Stanozololum | ChEBI | | Stromba | ChEBI | | Strombaject | ChEBI | | Winstrol | ChEBI | | (5a,17b)-17-Methyl-2'H-androst-2-eno[3,2-c]pyrazol-17-ol | HMDB | | 1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-Hexadecahydro-1,10a,12a-trimethyl-cyclopenta[7,8]phenanthro[2,3-c]pyrazol-1-ol | HMDB | | 17-Methyl-5a-androstano[3,2-c]pyrazol-17b-ol | HMDB | | 17-Methyl-pyrazolo[4',3':2,3]-5a-androstan-17b-ol | HMDB | | 17a-Methyl-17b-hydroxy-5a-androstano(3,2-c)pyrazole | HMDB | | 17b-Hydroxy-17-methyl-5a-androstano[3,2-c]pyrazole | HMDB | | 17b-Hydroxy-17a-methyl-5a-androstano[3,2-c]pyrazole | HMDB | | 2'H-5a-Androst-2-eno[3,2-c]pyrazol-17b-ol, 17-methyl- (8ci) | HMDB | | Anabol | HMDB | | Androstanazol | HMDB | | Androstanazolestanazol | HMDB | | Cyclopenta[7,8]phenanthro[2,3-c]pyrazole, 2'H-androst-2-eno[3,2-c]pyrazol-17-ol deriv. | HMDB | | Estazol | HMDB | | Stanazolol | HMDB | | Tevabolin | HMDB | | Win 14833 | HMDB | | Winstroid | HMDB | | Winstrol depot | HMDB | | Winstrol V | HMDB | | Sanofi winthrop brand OF stanozolol | HMDB | | Zambon brand OF stanozolol | HMDB | | Methylstanazol | HMDB | | Sanofi-synthelabo brand OF stanozolol | HMDB |
|
|---|
| Chemical Formula | C21H32N2O |
|---|
| Average Mass | 328.4916 Da |
|---|
| Monoisotopic Mass | 328.25146 Da |
|---|
| IUPAC Name | (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.0²,¹⁰.0⁴,⁸.0¹⁴,¹⁸]icosa-4,7-dien-17-ol |
|---|
| Traditional Name | stanozolol |
|---|
| CAS Registry Number | Not Available |
|---|
| SMILES | [H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC3=NNC=C3C[C@]12C |
|---|
| InChI Identifier | InChI=1S/C21H32N2O/c1-19-11-13-12-22-23-18(13)10-14(19)4-5-15-16(19)6-8-20(2)17(15)7-9-21(20,3)24/h12,14-17,24H,4-11H2,1-3H3,(H,22,23)/t14-,15+,16-,17-,19-,20-,21-/m0/s1 |
|---|
| InChI Key | LKAJKIOFIWVMDJ-IYRCEVNGSA-N |
|---|
| Experimental Spectra |
|---|
|
| Not Available | | Predicted Spectra |
|---|
|
| | Spectrum Type | Description | Depositor ID | Depositor Organization | Depositor | Deposition Date | View |
|---|
| 1D NMR | 13C NMR Spectrum (1D, 25 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 252 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 50 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 75 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 101 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 126 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 151 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 176 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 201 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 13C NMR Spectrum (1D, 226 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | | 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| | Chemical Shift Submissions |
|---|
|
| Not Available | | Species |
|---|
| Species of Origin | |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as estrane steroids. These are steroids with a structure based on the estrane skeleton. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Lipids and lipid-like molecules |
|---|
| Class | Steroids and steroid derivatives |
|---|
| Sub Class | Estrane steroids |
|---|
| Direct Parent | Estrane steroids |
|---|
| Alternative Parents | |
|---|
| Substituents | - Estrane-skeleton
- Hydroxysteroid
- 17-hydroxysteroid
- Azole
- Cyclic alcohol
- Pyrazole
- Tertiary alcohol
- Heteroaromatic compound
- Organoheterocyclic compound
- Azacycle
- Alcohol
- Organooxygen compound
- Organonitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Organic nitrogen compound
- Hydrocarbon derivative
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Physical Properties |
|---|
| State | Not Available |
|---|
| Experimental Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Predicted Properties | |
|---|
| General References | - Leinonen A, Kuuranne T, Kotiaho T, Kostiainen R: Screening of free 17-alkyl-substituted anabolic steroids in human urine by liquid chromatography-electrospray ionization tandem mass spectrometry. Steroids. 2004 Feb;69(2):101-9. doi: 10.1016/j.steroids.2003.10.007. [PubMed:15013688 ]
- Kintz P, Cirimele V, Sachs H, Jeanneau T, Ludes B: Testing for anabolic steroids in hair from two bodybuilders. Forensic Sci Int. 1999 May 17;101(3):209-16. doi: 10.1016/s0379-0738(99)00024-9. [PubMed:10404632 ]
- De Brabander HF, De Wasch K, van Ginkel LA, Sterk SS, Blokland MH, Delahaut P, Taillieu X, Dubois M, Arts CJ, van Baak MJ, Gramberg LG, Schilt R, van Bennekom EO, Courtheyn D, Vercammen J, Witkamp RF: Multi-laboratory study of the analysis and kinetics of stanozolol and its metabolites in treated calves. Analyst. 1998 Dec;123(12):2599-604. doi: 10.1039/a805110k. [PubMed:10435307 ]
- Fineschi V, Baroldi G, Monciotti F, Paglicci Reattelli L, Turillazzi E: Anabolic steroid abuse and cardiac sudden death: a pathologic study. Arch Pathol Lab Med. 2001 Feb;125(2):253-5. doi: 10.5858/2001-125-0253-ASAACS. [PubMed:11175645 ]
- Choi MH, Chung BC: N-isobutyloxycarbonylation for improved detection of 3'-hydroxystanozolol and its 17-epimer in doping control. Analyst. 2001 Mar;126(3):306-9. doi: 10.1039/b007929o. [PubMed:11284331 ]
|
|---|